louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06478329: The Effects of Progressive Core Stabilization Exercise Training
Official title: The Effects of Progressive Core Stabilization Exercise Training on Muscle Strength, Endurance, and Balance in Adolescent Female Volleyball Players
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Core Stability
Sports Physical Therapy
Adolescent
Sports Injury
Female Athlete
Lead sponsor: Halic University
Sponsor class: OTHER
Collaborators: name: Izmir Democracy University
name: Atlas University
First posted: 2024-06-27
Enrollment: 12
Sex: FEMALE
Minimum age (years): 12
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: A study to investigate the effects of 6 week-core stability training on adolescent volleyball players

Detailed description: Aim: The purpose of this study is to reveal effectiveness of 6-week progressive core stabilization exercise training on muscle strength, endurance, and balance in adolescent female volleyball players.

Method: Adolescent female volleyball players will be divided into study and control groups. Both groups will continue their routine ball training (30 times/day, totally 6-week), the SG will also participate in progressive core stabilization exercise training (45 min/session, 3 times/week, totally 6-week). Core muscle endurance (sit-ups test, lateral bridge test and Biering Sorenson Test), isokinetic muscle strength test of gluteus medius (Biodex 3 dynamometer in 1800/s, 2700/s, and 3600/s) and balance (Star Excursion Balance Test) will be evaluated in all players before and after 6-week follow-up.

Eligibility criteria: Inclusion Criteria:

* female volleyball player aged between 12-14 years
* being trained by the same trainer

Exclusion Criteria:

* having had a lower or upper extremity injury lasting less than 3 months
* having had a back-related operation
* being diagnosed with spondylosis-spondylolisthesis
* having acute low back pain
* lack of family permission or
* not being willingness.

Primary outcomes:
measure: Sit up test
timeFrame: 2 days
measure: Lateral bridge tests
timeFrame: 2 days
measure: Biering-Sorenson Test
timeFrame: 2 days
measure: Star Excursion Balance Test
timeFrame: 2 days
measure: Isokinetic Test
timeFrame: 1 week
Secondary outcomes:
measure: Weight
timeFrame: 1 day
measure: Height
timeFrame: 1 day
measure: Body Mass Index (BMI)
timeFrame: 1 day
measure: Menstruation period
timeFrame: 1 day
measure: Sports Age
timeFrame: 1 day
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01409629: Influence of a Computer Game on Youth's Choices of Activities
Official title: Influence of a Computer Game on Youth's Choices of Activities
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Study Individuals' Activity Choices After Playing a Computer Game
Lead sponsor: University at Buffalo
Sponsor class: OTHER
First posted: 2011-08-04
Enrollment: 80
Sex: ALL
Minimum age (years): 12
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Healthy adolescents ages 12-14

Brief summary: Study of activity choices after playing a computer game.


Eligibility criteria: Inclusion Criteria:

* Like study foods, healthy

Exclusion Criteria:

* Medical conditions, psychological disorders, food allergies

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Buffalo
country: United States
facility: Division of Behavioral Medicine
state: New York
Study officials:
References:
Clinical trial NCT01691729: Comparison Study of 3 Ostomy Products
Official title: A Randomized, Multicenter, Cross-Over Study Comparing the Performance of Three Ostomy Accessory Products
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Ostomy
Lead sponsor: ConvaTec Inc.
Sponsor class: INDUSTRY
First posted: 2012-09-25
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To purpose of the study is to evaluate and compare the efficacy of three ostomy accessory products.

Detailed description: The primary objective of this study was to evaluate and compare the efficacy of three ostomy accessory products in terms of leakage and wear time. Secondary objectives were to evaluate and compare the safety of three ostomy accessory products, and to assess and compare the performance of the three products in terms of use and overall impression.

Eligibility criteria: Inclusion Criteria:

* Has an ostomy
* Is at least 18 years of age
* Has a stoma for at least 3 months
* Other than thier ostomy is considered to have a healthy/stable health
* Is able to take care of their stoma

Exclusion Criteria:

* Known sensitivity to any of the ostomy devices or components
* Is undergoing chemotherapy or radiotherapy
* Has participated in a clinical study within the past 30 days
* Has a medical condition, in which in the opinion of the Investigator would not be a good candidate for the study and justifies exclusion

Primary outcomes:
measure: Leakage & Wear Time
timeFrame: 10 days
Secondary outcomes:
measure: Number of adverse events
timeFrame: 10 days
Other outcomes:
Locations:
city: Tucson
country: United States
facility: Independent Nurse Consultants
state: Arizona
city: Jacksonville
country: United States
facility: ET Nursing Services
state: Florida
city: Saint Joseph
country: United States
facility: Image Specialties
state: Missouri
city: Columbus
country: United States
facility: ID MED Inc.
state: Ohio
Study officials:
affiliation: ConvaTec Inc.
name: Kim Peters
role: STUDY_DIRECTOR
References:
Clinical trial NCT02193529: Dietary Intake After Laparoscopic Sleeve Gastrectomy -a 5 Year Study
Official title: Weight Loss and Metabolic Surgery Center Min-Sheng General Hospital
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Morbid Obesity
Keywords: sleeve gastrectomy, dietary intake, morbid obesity.
Lead sponsor: Min-Sheng General Hospital
Sponsor class: OTHER
First posted: 2014-07-17
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: morbid obesity patients received laparoscopic sleeve gastrectomy for more then 5 years. BMI above 40 kg/m2 when operation. Age 18-65 years old.

Brief summary: Weight reducing surgery is the only effective therapy for morbid obese patients.

Sleeve gastrectomy is a popular choice for bariatric surgery because of less sequela. There is poor knowledge about the nutritional status inpatients after LSG. The aim of our study was to investigate the relationship between dietary intake and weight loss after LSG.

Detailed description: Weight reducing surgery is the only effective therapy for morbid obese patients. Restrictive type surgery is safer than mal-absorptive type surgery. Laparoscopic sleeve gastrectomy is an effective surgery. In laparoscopic sleeve gastrectomy (LSG), about 90% of the stomach is surgically removed by vertical resection of the great curvature side, including the fundus. The simplicity of surgical procedures, the low occurrence of complications, and the efficiency of reducing excess weight have made LSG as a popular choice for bariatric surgery. After LSG, the amount of food eaten is drastically reduced, leading to nutritional deficiencies potentially. There is poor knowledge about the nutritional status inpatients after LSG. Some literatures suggest that LSG results in less nutritional deficiencies than Roux-en-Y gastric bypass. The aim of our study was to investigate the relationship between dietary intake and weight loss after LSG.

Eligibility criteria: Inclusion Criteria:

* morbid obesity patients received laparoscopic sleeve gastrectomy for more then 5 years.

BMI above 40 kg/m2 when operation. Age 18-65 years old. No major psychosis or binge eating disorder. No endocrine disease. failed to lose weight with medical therapy.

Exclusion Criteria:

* current hepatitis, under steroid treatment,cancer, thyroid disease,alcoholism.

Primary outcomes:
measure: Dietary intake after laparoscopic sleeve gastrectomy 5 years
timeFrame: up to 18 months
Secondary outcomes:
Other outcomes:
Locations:
city: Taoyuan
country: Taiwan
facility: Weight Loss and Metabolic Surgery Center Min-Sheng General Hospital
Study officials:
affiliation: School of Nutrition and Health Sciences,Taipei Medical University
name: Ju J Chou, university
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04671329: A Prospective, Multi-site Clinical Study to Collect User Feedback Using Affirm® Contrast Biopsy
Official title: A Prospective, Multi-site Clinical Study to Collect User Feedback Using Affirm® Contrast Biopsy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Cancer
Keywords: Breast Biopsy, Contrast Biopsy
Lead sponsor: Hologic, Inc.
Sponsor class: INDUSTRY
First posted: 2020-12-17
Enrollment: 67
Sex: FEMALE
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Currently, if a radiologist finds a suspicious lesion seen only on a diagnostic Contrast Enhanced Digital Mammography (CEDM) exam requiring biopsy the biopsy procedure would likely be performed with MRI guidance because there are currently limited solutions to biopsy with CEDM guidance. Affirm Contrast Biopsy will provide an additional solution to biopsy/localize lesions found by using a CEDM imaging modality.


Eligibility criteria: Inclusion Criteria:

* Females aged 40 years of age or older recommended for biopsy who have had a suspicious finding on previous contrast enhanced imaging or have lesions that may be occult under other modalities
* Subject is able to read, understand, and sign the study specific informed consent form after the nature of the study has been fully explained to them

Exclusion Criteria:

* Subjects who require a Legally Authorized Representative (LAR) for Informed Consent
* Subjects who, based on the physician's judgement, may be at increased risk for complications associated with renal function, anticoagulant therapy, or bleeding disorders
* Subjects who have had a previous allergic reaction to IV contrast agent

Primary outcomes:
measure: Number of Participants With Technical Success
timeFrame: Up to 1h (time to complete the procedure)
Secondary outcomes:
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Mayo Clinic
state: Arizona
city: Pittsburgh
country: United States
facility: University of Pittsburgh Medical Center
state: Pennsylvania
Study officials:
References:
Clinical trial NCT06856629: The Immediate Physiological and Perceptual Response to Blood-flow Restricted Strength Training with Eccentric Loading
Official title: The Immediate Physiological and Perceptual Response to Blood-flow Restricted Strength Training with Eccentric Loading (E-BFR): a Randomised Crossover Study in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Healthy
Keywords: Blood-flow restriction training
acute physiological response
eccentric training
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2025-03-04
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: With random sequence allocation
Primary purpose: OTHER

Brief summary: Decreasing workloads in strength training makes it more tolerable for a broad range of people. When designed as blood-flow restriction training, similar gains in strength and muscle mass are achieved compared to traditional training. Adding high training loads to blood-flow restriction training only in the eccentric phase (BFR-ECC) might achieve superior gains in muscle strength while still maximizing tolerability of the training stimuli.

This study aims to investigate the acute physiological and perceptual response of blood-flow restriction training with eccentric loading in comparison to traditional eccentric training. The study recruits healthy individuals ≥ 18 years.


Eligibility criteria: Inclusion Criteria:

* Clinically Healthy

Exclusion Criteria:

* Physical or intellectual impairment precluding informed consent or protocol adherence
* Pain during exercise of any origin
* History of thromboembolic event in the lower extremity
* Known pregnancy (no testing is carried out)

Primary outcomes:
measure: minute ventilation
timeFrame: During the intervention (i.e., exercise) for 10 minutes
Secondary outcomes:
measure: Other variables from breath-by-breath analysis
timeFrame: During the intervention (i.e., exercise) for 10 minutes
measure: Rate of perceived exertion
timeFrame: Immediately after the intervention (i.e., exercise)
measure: Near-infrared spectroscopy of the vastus lateralis
timeFrame: During the intervention (i.e., exercise) for 10 minutes
measure: Delayed onset muscle soreness
timeFrame: 24, 48, and 72 hours after each of the intervention (i.e., exercise)
measure: Feasibility and tolerability
timeFrame: After study completion (i.e., after the second study visit, up to 2 weeks)
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University of Zurich
Study officials:
References:
Clinical trial NCT02521129: A New Track Ablation Device for Liver Biopsy: A Feasibility Study
Official title: A New Track Ablation Device for Liver Biopsy: A Feasibility Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Liver Neoplasms
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2015-08-13
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effectiveness and safety of a new biopsy track ablation device for liver biopsy.

Detailed description: Background:

* Percutaneous biopsy for hepatic masses has a potential risk of bleeding and peritoneal tumor seeding.
* A new device for biopsy track ablation has been invented to reduce the risk of bleeding and peritoneal tumor seeding.

Method:

* Routine percutaneous biopsy for hepatic masses is performed.
* Immediate after obtaining tissue, biopsy needle track is ablated with a new biopsy tract ablator.
* Immediate (with ultrasound) and 24 hours (with CT scan) after procedure, occurrence of complications is evaluated.

Eligibility criteria: Inclusion Criteria:

* patients with a hepatic mass on CT scan or MRI
* patients who are referred for percutaneous biopsy of a hepatic mass
* patients with normal range of platelet count and coagulation test

Exclusion Criteria:

* pregnant women
* patients with ascites
* Uncooperative patients

Primary outcomes:
measure: Number of participants with complications
timeFrame: within 24 hours after procedure
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Samsung Medical Center
name: Hyunchul Rhim, professor
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD; American Association for the Study of Liver Diseases. Liver biopsy. Hepatology. 2009 Mar;49(3):1017-44. doi: 10.1002/hep.22742. No abstract available.
citation: Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199. No abstract available.
Clinical trial NCT01186029: Comparison of Adding EMEND to PONV/PDNV Treatment Regimen
Official title: A Comparison Study to Determine the Increased Efficacy of Adding EMEND to the Treatment Regimen for Post-Discharge and Post-Operative Nausea and Vomiting
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Postoperative Nausea and Vomiting
Keywords: Nausea and Vomiting
Lead sponsor: University of Nebraska
Sponsor class: OTHER
First posted: 2010-08-20
Enrollment: 0
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study is looking at whether the addition of Aprepitant (Emend), an antiemetic, will provide added efficacy if added to 2 drugs that are already used as a standard of care for post-operative nausea and vomiting and post-discharge nausea and vomiting.

Detailed description: This study is looking at whether the addition of a fairly new drug for the treatment of post-operative nausea and vomiting (PONV) and post-discharge nausea and vomiting (PDNV) will provide added efficacy if added to 2 drugs that are already used as a standard of care for PONV and PDNV.

The patients that will be looked at will be deemed at higher risk for PONV and PDNV based on the procedure they are having done and/or on patient risk factors.

Eligibility criteria: Inclusion Criteria:

* patients with at least 2 of the common risk factors for PONV/PDNV; patients having a procedure deemed at high risk for PONV/PDNV

Exclusion Criteria:

* patients under 19 years of age; pregnant and breast-feeding patients

Primary outcomes:
measure: EMEND Added to Standard Treatment of Post-operative and Post-Discharge Nausea and Vomiting
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Nebraska
name: Maria A Michaelis, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02313129: Causes of Comorbid Infertility Among Women With Rheumatoid Arthritis
Official title: Causes of Comorbid Infertility Among Women With Rheumatoid Arthritis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infertility
Rheumatoid Arthritis
Keywords: Infertility
Rheumatoid Arthritis
Lead sponsor: Duke University
Sponsor class: OTHER
First posted: 2014-12-09
Enrollment: 150
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Rheumatoid Arthritis Women and Health Control Women

Brief summary: The purpose of this study is to increase our understanding of infertility in women with Rheumatoid Arthritis (RA). In this study the study team will compare the differences in ovarian reserve (the ability to provide egg cells that are capable of fertilization), the frequency of ovulation and the number of pregnancies between women with and without RA. It is possible that RA activity and medications limit ovarian reserve and ovulation, which may increase infertility among women with RA. There are several suspected causes for infertility in RA, including age-related fertility decline, inflammatory changes that impact endometrial receptivity and discourage implantation, accelerated ovarian decline due to certain arthritis medications and increased frequency of anovulation (a menstrual cycle during which ovaries do not release an egg) due to RA activity.

This study is the first step toward our long term goal of increasing the ability of all women with RA to build the family they desire.


Eligibility criteria: Inclusion Criteria:

1. RA cohort: Women diagnosed with RA (2010 ACR/EULAR criteria) at least one year prior to enrollment
2. Healthy cohort: Women without autoimmune disease

Exclusion Criteria:

1. Unilateral or bilateral ovarian surgery
2. Prior exposure to known or possible ovary-toxic medications (e.g., cyclophosphamide, other chemotherapeutic agents)

Primary outcomes:
measure: Ovarian Reserve between women with and without RA
timeFrame: At study enrollment
measure: Ovulation Frequency between women with and without RA
timeFrame: At study enrollment
Secondary outcomes:
measure: Rates of Infertility between women with and without RA
timeFrame: At study enrollment
measure: Number of Pregnancies between women with and without RA
timeFrame: At study enrollment
measure: Age at attempted and actual conception between women with and without RA
timeFrame: At study enrollment
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
Study officials:
affiliation: Duke University
name: Megan Clowse, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06423729: Effect of Nicorandil in Type 2 Diabetic Obese Patients
Official title: Clinical Study Evaluating the Effect of Nicorandil in Type 2 Diabetic Obese Patients Treated With Sulfonylurea
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
PHASE3
Conditions: Diabetes Mellitus, Type 2
Keywords: Type 2 DM, Nicorandil, Obesity
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2024-05-21
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: 1. Evaluating the effect of nicorandil on glycemic control of diabetic obese patients treated with sulfonylureas.
2. Investigating the effect of nicorandil on body weight of diabetic obese patients treated with sulfonylureas.


Eligibility criteria: Inclusion Criteria:

* Diabetes duration ranged from 1 to 10 years.
* Body mass index (BMI) \>30 Kg/m2.
* The selected patients are treated with sulfonylureas alone.
* The age of selected patient ranged from 18 and 60 years.

Exclusion Criteria:

* Pregnant and lactating females.
* Patients with hypersensitivity to nicorandil.
* Uncontrolled hypertension and its antihypertensive medications
* Severe renal or hepatic disease.

Primary outcomes:
measure: Change in HbA1c level
timeFrame: The participants will be assessed before initiation of the study (baseline), and at the end of the study after 3 months.
measure: Change in body weight.
timeFrame: The participants will be assessed before initiation of the study (baseline), and at the end of the study after 3 months.
measure: Change in Body mass index (BMI)
timeFrame: The participants will be assessed before initiation of the study (baseline), and at the end of the study after 3 months.
measure: Change in Visceral adiposity index (VAI).
timeFrame: The participants will be assessed before initiation of the study (baseline), and at the end of the study after 3 months.
Secondary outcomes:
measure: Change in Adiponenctin, Interleukin-6 (IL-6) and Nitric oxide (NO) serum levels.
timeFrame: The participants will be assessed before initiation of the study (baseline), and at the end of the study after 3 months.
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Faculty of Pharmacy, Tanta University
Study officials:
References: